{"id":"NCT00468312","sponsor":"Organon and Co","briefTitle":"Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)","officialTitle":"Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2007-07","completion":"2007-07","firstPosted":"2007-05-02","resultsPosted":"2010-06-22","lastUpdate":"2022-02-09"},"enrollment":429,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Mometasone furoate nasal spray","otherNames":["Nasonex"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Mometasone Furoate Nasal Spray (MFNS)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.","primaryOutcome":{"measure":"Change From Baseline in Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15","timeFrame":"Screening through 15 days daily","effectByArm":[{"arm":"Mometasone Furoate Nasal Spray (MFNS)","deltaMin":9.31,"sd":1.6},{"arm":"Placebo","deltaMin":9.31,"sd":1.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20434199"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":220},"commonTop":[]}}